Side-by-side · Research reference
ChonlutenvsHumanin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/38 cited
BAnimal-StrongHUMAN-REVIEWED14/52 cited
Chonluten
Khavinson Bioregulator · Bronchial Mucosa
Oral · Sublingual · Per Protocol
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
Chonluten
Humanin
Primary target
Bronchial epithelial cells and respiratory mucosa tissue complexes
Pathway
Bioregulatory peptide interaction → modulation of proliferative and inflammatory pathways in monocyte/macrophage populationsAvolio 2022
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Regulation of proliferative activity and inflammatory mediator production in respiratory-associated immune cellsAvolio 2022
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Feedback intact?
—
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Origin
Khavinson bioregulator peptide complex derived from bronchial mucosa tissue extract methodology
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Antibody development
—
Not reported in animal models
02Dosage Protocols
Parameter
Chonluten
Humanin
Typical protocol dose
10–20 mg / day
Russian bioregulator tradition dosing; not standardized in Western literature.
—
Frequency
Once or twice daily
Daily (IP)
Route
Oral (capsule) or sublingual
Sublingual claimed for enhanced bioavailability; not validated.
—
Duration
10–30 days per cycle
Traditional Khavinson protocol; cyclic administration common.
8–12 weeks in animal studies
Clinical validation
None (PubMed indexed)
—
Standard experimental dose (HNG)
—
4 mg/kg IP (rat)
Most common dose in rodent models.
Ex vivo bone culture
—
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
Human data
—
None — no clinical trials reported
Analog (HNG)
—
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
03Metabolic / Fat Loss Evidence
Parameter
Chonluten
Humanin
Direct fat loss evidence
—
None
Mechanism overlap
—
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
04Side Effects & Safety
Parameter
Chonluten
Humanin
Documented adverse events
No published safety data in PubMed-indexed literature
—
Theoretical risks
Peptide hypersensitivity, GI intolerance (uncharacterized)
—
Drug interactions
Unknown — no pharmacokinetic studies available
—
Pregnancy / lactation
No data — avoid
—
Animal model safety
—
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
Human safety data
—
None — no clinical trials
Theoretical fibrillation risk
—
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
Injection site reaction
—
Not reported in animal studies (IP route)
Reproductive safety
—
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
Absolute Contraindications
Chonluten
- ·Known hypersensitivity to peptide components
Humanin
- ·Unknown — no human data
Relative Contraindications
Chonluten
- ·Pregnancy and lactation (insufficient data)
- ·Active malignancy (theoretical bioregulator concern)
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
05Administration Protocol
Parameter
Chonluten
Humanin
1. Preparation
Typically supplied as capsules or sublingual tablets. No reconstitution required. Store in cool, dry place away from light.
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
2. Oral route
Swallow capsule with water, 20–30 minutes before meals or as directed. Traditional Khavinson protocol emphasizes empty stomach for absorption.
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
3. Sublingual route
Place tablet under tongue, allow dissolution for 1–2 minutes. Avoid swallowing immediately. Claimed to bypass first-pass metabolism.
Daily administration in animal studies. Optimal timing not characterized.
4. Timing
Morning dose preferred; may split into twice-daily if higher dose used. Consistency emphasized in bioregulator protocols.
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
5. Cycle protocol
10–30 day cycles common in Russian tradition. Rest period of 1–3 months between cycles often recommended, though no published evidence for this approach.
No FDA approval, no IND, no clinical trials. Experimental research tool only.
06Stack Synergy
Chonluten
— no documented stacks
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling